Navigation Links
Medivation Announces Presentation of Full Top-Line Data From,Dimebon Six-Month Trial at Major International Alzheimer's Disease,Conference

SAN FRANCISCO, March 19, 2007 /PRNewswire-FirstCall/ -- Medivation, Inc. today announced that six-month results from its randomized, double-blinded, placebo-controlled Phase 2 efficacy trial of Dimebon(TM) in patients with mild-to-moderate Alzheimer's disease demonstrated that patients treated with Dimebon were significantly improved compared to patients taking placebo on all five efficacy endpoints studied, which assessed cognitive function, memory, ability to perform tasks of daily living, global function and behavior.

Full top-line data from this trial were presented yesterday for the first time as an oral presentation (abstract #1662) at the 8th International Conference on Alzheimer's and Parkinson's Diseases: Progress and New Perspectives, in Salzburg, Austria, by the study's lead investigator, Rachelle S. Doody, M.D., Ph.D., the Effie Marie Cain Chair in Alzheimer's Disease Research at the Alzheimer's Disease and Memory Disorders Center, in Houston.

New data presented in Salzburg included the magnitude and levels of statistical significance by which the Dimebon-treated patients outperformed the placebo-treated patients on the Mini Mental State Exam (MMSE: p<0.0001), the Alzheimer's Disease Cooperative Study Group-Activities of Daily Living (ADCS-ADL: p=0.002), and the Neuropsychiatric Inventory (NPI: p=0.006). As previously reported, Dimebon-treated patients also demonstrated significant improvement versus placebo on both the primary and key secondary endpoints in this study -- the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog: p<0.0001) and the Clinician's Interview-Based Impression of Change with a caregiver interview (CIBIC-plus: p<0.0001). Dimebon was well tolerated in this study.

"In my experience, the results of this study are particularly striking for two primary reasons," said Dr. Doody. "First, Dimebon produced statistically significant improvement over pl
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
2. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
3. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
4. Medivation Announces First U.S. Presentation of Data From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:10/6/2008)...he door to the understanding of and possible ...ancer, BILLERICA, Mass., Oct. 6 /- S...the first ever analytical instrument for the,kinet... and cytoplasmic,glycolysis in cells in a 96 well ...ing cellular bioenergetics have been relatively un...
(Date:10/6/2008)...tudies with Durezol Dosed Prior to Surgery, TAMPA..., Inc., a,privately held ophthalmic-focused biopha...TM) (difluprednate ophthalmic emulsion) 0.05% is n...oved by the U.S. Food and,Drug Administration in J...ndicated for the treatment of inflammation and pai...
(Date:10/6/2008)...ll Scheduled for 9:00 AM ET Today -, SEATTLE, Oct... (Nasdaq:,DNDN) announced today that it has comple...andomized, double-blind, placebo-controlled IMPACT...ent, also known as D9902B),clinical trial designed...ational active cellular immunotherapy PROVENGE(R) ...
(Date:10/6/2008)...at drinking polyphenol-rich 100% Concord grape,jui...ergy intake or body,weight, CONCORD, Mass., Oct. ...phenol-rich Concord grape juice did not cause sign...es in appetite and was shown to reduce waist,circu...th Annual Meeting of,the American College of Nutri...
Breaking Medicine Technology:Seahorse Bioscience Announces the XF96 Extracellular Flux Analyzer for Cellular Bioenergetics 2Seahorse Bioscience Announces the XF96 Extracellular Flux Analyzer for Cellular Bioenergetics 3Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 2Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 3Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 4Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 5Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 2Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 3Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 4Concord Grape Juice Has No Significant Impact on Body Weight 2Concord Grape Juice Has No Significant Impact on Body Weight 3Kensey Nash to Participate in the Sidoti Fifth Annual Palm Beach Emerging Growth Institutional Investor Forum Conference 2642 1New Benefactors Show Support for CDA4CDT 3A 2638 1New Benefactors Show Support for CDA4CDT 3A 2638 2New Benefactors Show Support for CDA4CDT 3A 2638 3New Benefactors Show Support for CDA4CDT 3A 2638 4New Benefactors Show Support for CDA4CDT 3A 2638 5New Benefactors Show Support for CDA4CDT 3A 2638 6New Benefactors Show Support for CDA4CDT 3A 2638 7Newly discovered virus linked to deadly skin cancer 9721 1Newly discovered virus linked to deadly skin cancer 9721 2Newly discovered virus linked to deadly skin cancer 9721 3Newly discovered virus linked to deadly skin cancer 9721 4Gene That Creates Cerebral Cortex Discovered 9718 1
...ly to subsequently,respond, have substantially mor...ange in treatment strategy, COLORADO SPRINGS, Colo...ta presented at the 2007 International Congress on...sychotic drug,response be assessed earlier than is...zophrenia treatment paradigm for when to,evaluate ...
...ector National,Alliance on Mental Illness (NAMI), ...ire/ -- Today,the Archives of General Psychiatry p...ial treatments for bipolar disorder,"Psychosocial...w up,study to one released last Thursday in the Ne...tidepressants in the treatment of,bipolar disorder...
Other Medicine Technology:New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 2New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 3New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 4New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 5New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 6Latest NIMH Study on Bipolar Disorder 2Latest NIMH Study on Bipolar Disorder 3
(Date:10/6/2008)... WASHINGTON, Oct. 6 /PRNewswire-USNewswire/ -- ...nst several companies alleging that they,submitted...kbacks and the,establishment of sham durable medic...nt announced today. The companies are McKesson Cor...MediNet), GGNSC Holdings LLC,Golden Gate Ancillar...
(Date:10/6/2008)... A study led by researchers at the University of ...that use of oral Vitamin D supplements bolsters pr...n the skin, and may help prevent skin infections t...most common form of eczema. , The study led by ...and chief of the Division of Dermatology at the UC...
(Date:10/6/2008)... SAN DIEGO, Oct. 6 /PRNewswire/ -- Developed in... of Pacific Palisades, CA is introducing,Revolutio...y into the,Plastic Surgery office of Dr. Steve Lav... XS-300(TM), is the first of its kind, and is base...hnology combined with,innovative proprietary softw...
(Date:10/6/2008)... Vision Audio Inc. has an...deo game designed to help train children with auti...Se Off-Road is a fun, non-violent learning experie...participate in their enhanced sound-based therapy,...dio ( http://www.easecd.com ). , ...
Breaking Medicine News(10 mins):Health News:U.S. Intervenes in False Claims Act Suit Against McKesson Corp. and Golden Horizons Nursing Homes 2Health News:Oral vitamin D may help prevent some skin infections 2Health News:Plan Your Breasts in 3-D 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 3
...e-to-speech" project in Singapore is using a custo...ally improve the lives of the intellectually disab...ing with homemade pictures, the handheld innovatio...express their needs in such everyday tasks as orde...
...reated with Interferon (IFN)to treat chronic hepa... during treatment phase itself//. Retinopathy can ...tment, says the researchers in a study published ...gy & Visual Science (IOVS)in the January 2007 iss...
...t government-run hospitals in Rajasthan will now h...instead of a brand name//, according to Health Min...this regard to all government medical colleges, ho...ntres, community health centres and dispensaries,"...
...y dwellings were thought to be far cleaner and hea...itish researchers say this is not true- inner citi.... Market analysts CACI and TNS analyzed smoking a... understand the unhealthiest places in England, Wa...
Other Medicine News:
... magnification for advanced surgical procedures. P...ven at the highest magnification. 3.5x, 4.5x and 5...ion is ideal for surgical applications. Precision ...duce a superior image. The compact abd lightweight...
... high power negative lens delivering magnification...system is ease of use. Movement whilst maintaining...depth of field. The ultra lightweight aluminum bar... stability for the mounted loupes and optimal foca...
Keeler Galilean loupes are ideal for general dental and surgical work when increased magnification and a large field of view of required., ,Keeler loupes are laser aligned, lightweight and comfor
Used for maintaining and forming the anterior chamber by the injection and removal of fluids, air miotics, and viscoeastic substances, as well as keeping the cornea moist during surgery. 4 mm from be
Medicine Products: